# Bortezomib in Treating Patients With Newly Diagnosed Multiple Myeloma

> **NCT00075881** · PHASE2 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 44 (actual)

## Conditions studied

- Stage I Multiple Myeloma
- Stage II Multiple Myeloma
- Stage III Multiple Myeloma

## Interventions

- **DRUG:** bortezomib
- **OTHER:** laboratory biomarker analysis

## Key facts

- **NCT ID:** NCT00075881
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-01
- **Primary completion:** 2012-10
- **Final completion:** 2012-10
- **Target enrollment:** 44 (ACTUAL)
- **Last updated:** 2014-06-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00075881

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00075881, "Bortezomib in Treating Patients With Newly Diagnosed Multiple Myeloma". Retrieved via AI Analytics 2026-08-11 from https://api.ai-analytics.org/clinical/NCT00075881. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*